• Luminescent ATP Cell Viability Assay Kit I Workflow

  2026-08-26

  Turn ATP-dependent luminescence into a rapid, high-sensitivity cell viability measurement for proliferation, drug combination, and ferroptosis studies. This workflow shows how to use the Luminescent ATP Cell Viability Assay Kit I to quantify CFX–RSL3 responses while avoiding common interpretation and plate-performance errors.

• Tigecycline Workflows for MDR Bacteria Research

  2026-08-25

  Tigecycline provides a practical phenotypic comparator for multidrug-resistant bacterial research, from broth microdilution to genotype-linked transmission studies. This workflow-oriented guide connects its 30S-targeted activity with CREC plasmid surveillance, MRSA research, troubleshooting, and translational assay design.

• Tigecycline Workflows for MDR Research

  2026-08-25

  Tigecycline provides a practical glycylcycline antibiotic framework for studying resistant pathogens, ribosome-targeted inhibition, and phenotypic susceptibility. This guide translates recent CREC transmission findings into reproducible assay workflows, comparator strategies, and troubleshooting decisions for MRSA, GISA, and multidrug-resistant bacteria research.

• Tetraethylammonium chloride in Cell Assays

  2026-08-24

  This scenario-based guide explains how Tetraethylammonium chloride, SKU B7262, can strengthen mechanistic interpretation in cell viability, proliferation, and cytotoxicity workflows without being mistaken for a generic viability reagent. It connects K+ channel blockade, solvent handling, orthogonal readouts, and supplier-quality checks to practical laboratory decisions.

• Ceapin-A7 and the Next Phase of ER Stress Research

  2026-08-24

  Ceapin-A7 provides a selective way to interrogate ATF6α signaling alongside the PERK–JAK1–STAT3 axis implicated in nucleus pulposus cell pyroptosis. This thought-leadership analysis connects pathway-selective pharmacology with translational study design for intervertebral disc degeneration and broader endoplasmic reticulum stress research.

• AP20187 Workflows for Controlled Dimerization

  2026-08-23

  AP20187 gives researchers temporal control over engineered signaling proteins, enabling conditional gene expression, regulated cell therapy, and metabolic assays. This guide connects practical dimerizer workflows with a chronic intermittent hypoxia pain model while clearly separating validated findings from assay-development opportunities.

• HyperScript™ Reverse Transcriptase for RNA Workflows

  2026-08-22

  Learn how HyperScript™ Reverse Transcriptase supports cDNA synthesis for qPCR when RNA is scarce, structured, or difficult to copy. This workflow-focused guide connects the enzyme’s thermal stability and reduced RNase H activity to transcriptomic validation in RPE/choroid and other demanding assays.

• FAST Food-Grade Nutraceutical Nanoparticles: Study Analysis

  2026-08-22

  This study evaluates Facilitated Self-Assembling Technology as a surfactant-free, food-grade route for producing stable nanoparticles from poorly soluble nutraceuticals. Its strongest evidence concerns particle formation, colloidal stability, simulated gastric behavior, and in-vitro compatibility, while direct enhancement of oral bioavailability remains to be demonstrated.

• Belinostat (PXD101): HDAC Research Guide

  2026-08-21

  Belinostat, also called PXD101, is a hydroxamate-type pan-HDAC inhibitor for preclinical epigenetic cancer research. Product data report nanomolar HDAC activity, histone H3/H4 acetylation, tumor-cell growth inhibition, and a bladder-tumor benchmark in mice, while these findings do not establish clinical efficacy.

• Tropifexor: An Assay-First FXR Research Guide

  2026-08-20

  Tropifexor (LJN452) is a potent FXR agonist for connecting receptor activation with intestinal barrier and metabolic phenotypes. This assay-first guide explains how the neonatal piglet and patient-derived organoid study can inform model selection, endpoints, controls, and interpretation.

• AZD8055 Protocol Guide for mTOR Pathway Studies

  2026-08-20

  AZD8055 is a selective ATP-competitive mTOR inhibitor for controlled studies of mTORC1/mTORC2 signaling, cancer cell proliferation, and selected metabolic endpoints. It is appropriate for preclinical mechanistic work but should not be selected when water solubility, validated clinical efficacy, or a defined clinical dosing regimen is essential.

• Quercetin Protects Cataract Lenses via Hippo Signaling

  2026-08-19

  This 2025 study combines network pharmacology, a UVB-induced cataract mouse model, and oxidatively injured lens epithelial cells to investigate how quercetin protects the lens. Its central contribution is the use of α-hederin-mediated pathway reactivation to connect Hippo signaling changes with oxidative stress, epithelial proliferation, and cataract-related tissue damage.

• From RNA Cargo to Translational Readout

  2026-08-19

  A translational framework for using dual-fluorescence mRNA to separate delivery, intracellular trafficking, and protein expression—and to connect those measurements with emerging RNA nanoparticle design rules.

• Midecamycin: Designing Better Antibacterial Assays

  2026-08-18

  Midecamycin is an acetoxy-substituted macrolide antibiotic for targeted bacterial protein synthesis studies. This guide connects ribosome-level pharmacology with perfusion-aware assay design to improve interpretation of antibacterial data.

• Sulfachloropyridazine: From DHPS to Microbiome Strategy

  2026-08-18

  Sulfachloropyridazine offers translational researchers a practical bridge from DHPS biochemistry to antimicrobial phenotyping and microbiome-aware infection models. This article examines how to validate target engagement, interpret cecal microbiome findings, and design research workflows that distinguish direct antibacterial effects from broader ecological and metabolic responses.

8671 records 3/579 page Previous Next 12345 下5页 Last page